The phenomenon of pseudoprogression in cancer immunotherapy: is everything so unambiguous?
When evaluating the effect of therapy for malignant neoplasms with inhibitors of CTLA-4, PD-1 and PD-L1, the phenomenon of pseudoprogression may occur. Pseudoprogression is an increase in the volume of tumor tissue due to immunocompetent cells (lymphocytes, macrophages) mobilized into the tumor focu...
Saved in:
Main Authors: | Vladislav O. Sarzhevskiy, Vladimir Ia. Melnichenko, Irina V. Panshina, Nikita E. Mochkin, Vladimir S. Bogatyrov, Maria M. Borshevetskaya, Elena G. Smirnova, Anna E. Bannikova, Anastasia A. Samoylova, Aysel A. Mamedova, Anatolij A. Rukavitsin, Sergei S. Vasilev, Oleg Iu. Bronov |
---|---|
Format: | article |
Language: | RU |
Published: |
IP Habib O.N.
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/087c99ed4f454995bde9965434ae6e7f |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma
by: Virginia Liberini, et al.
Published: (2021) -
Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
by: Peiyi Xie, et al.
Published: (2021) -
Dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives
by: Denis I. Yudin, et al.
Published: (2021) -
Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy
by: Chi Yan, et al.
Published: (2021) -
Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma
by: Yan Li, et al.
Published: (2021)